Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma

• Published in: Cancers Vol. 13; no. 17; p. 4469
• Main Authors: Lin, Zili, Wu, Ziyi, Luo, Wei
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 05.09.2021; MDPI
• Subjects: Antigens; Bone cancer; Bone tumors; Cancer therapies; CAR-T therapy; Cell therapy; Chemotherapy; Chimeric antigen receptors; Cytokine storm; Drug dosages; Epidermal growth factor; Experiments; immune checkpoint; Immunotherapy; Kinases; Leukemia; Ligands; Lymphocytes; Lymphocytes T; Lymphoma; Medical prognosis; Medical research; Metastases; Metastasis; Neuroblastoma; Osteosarcoma; Patients; Proteins; Remission (Medicine); Review; Sarcoma; Solid tumors; targeted therapy; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13174469

Osteosarcoma (OS) is the most common malignant bone tumor, arising mainly in children and adolescents. With the introduction of multiagent chemotherapy, the treatments of OS have remarkably improved, but the prognosis for patients with metastases is still poor, with a five-year survival rate of 20%. In addition, adverse effects brought by traditional treatments, including radical surgery and systemic chemotherapy, may seriously affect the survival quality of patients. Therefore, new treatments for OS await exploitation. As a novel immunotherapy, chimeric antigen receptor (CAR) T-cell therapy has achieved encouraging results in treating cancer in recent years, especially in leukemia and lymphoma. Furthermore, researchers have recently focused on CAR-T therapy in solid tumors, including OS. In this review, we summarize the safety, specificity, and clinical transformation of the targets in treating OS and point out the direction for further research.